Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207075 · ClinicalTrials.gov registry record
Measuring Active Microglia in Progressive Multiple Sclerosis
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 50
- Enrollment target
NCT02207075 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 50 participants.
The verdict
NCT02207075 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This is pilot study designed to quantifying the innate immune inflammatory burden in a cohort of secondary progressive multiple sclerosis subjects. Innate immunity is recognized as a major cause of tissue injury in central nervous system (CNS) disease. Our hypothesis is that the innate immune response is heightened in SPMS as compared to healthy controls (HC's) and this activity increases over time and correlates with ongoing neuronal loss and disability. The investigators will test this hypothesis by using highly specific molecular imaging techniques, specifically PET, in conjunction with high field MRI. The investigators will utilize the PET radioligand \[11C\]PK11195 which will be used as a marker of activated macrophages/microglia. The investigators will correlate \[11C\]PK11195 uptake with conventional measures of inflammation and neuronal integrity on high-resolution MRI. SPMS subjects will have two baseline \[11C\]PK-11195 PET scans (separated by 24 to 72 hours, test-retest) and subsequent scans at 6, 12 and 24 months. SPMS Subjects will have brain MRI's at baseline, 6, 12 and 24 months. Healthy Controls will have 2 baseline PET scans and one MRI.
Interventions
- DRUG [C11]PK-1195 PET scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-07 |
| Est. Completion | 2020-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207075
The ClinicalTrials.gov registry entry for NCT02207075 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [C11]PK-1195 PET scan is the first listed.
NCT02207075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207075 about?
NCT02207075 is a clinical study titled "Measuring Active Microglia in Progressive Multiple Sclerosis". This is pilot study designed to quantifying the innate immune inflammatory burden in a cohort of secondary progressive multiple sclerosis subjects. Innate immunity is recognized as a major cause of tissue injury in central nervous system (CNS) disease. Our hypothesis is that the innate immune respon...
What is the current status of trial NCT02207075?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2014-07. Estimated completion is 2020-12.
What interventions are being tested in trial NCT02207075?
The interventions under investigation include: [C11]PK-1195 PET scan (DRUG).
Who is sponsoring clinical trial NCT02207075?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.